ReviewJournal of endocrinological investigation2019
A 2019 update on TSH-secreting pituitary adenomas.
Review in Journal of endocrinological investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 106 citations in OpenAlex.
- Can a novel drug dose be used for T3 suppression test?Endocrine · 2023Trial
- Article
- Hyperthyroidism, acromegaly, and hyperprolactinemia in a patient with a mature plurihormonal PIT-1 lineage adenoma.JCEM case reports · 2026Article
- Thyrotropin/growth hormone co-secreting pituitary adenoma with pancytopenia: a case report.Journal of medical case reports · 2026Article
- Article
- Thyroid hormone resistance beta and autoimmune thyroid disease - a family case study highlighting diagnostic and therapeutic challenges.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Differential diagnosis of familial dysalbuminemic hyperthyroxinemia , RTH, and TSHomas: A single-center retrospective analysis.Endocrine · 2026Article
- Article
- Ageing and pituitary neuroendocrine tumours (PitNETs): from bench to bedside.Endocrine-related cancer · 2026Review
- Case Report: Development of a thyrotropinoma in a patient with thyroid hemiagenesis.Frontiers in endocrinology · 2026Article
- Article
- A subtle initial clinical presentation of a TSH-secreting PitNET.Endocrinology, diabetes & metabolism case reports · 2025Article
- Long-term surgical outcomes in TSH-secreting pituitary adenomas: the hidden burden of asymptomatic hyperthyroidism.Endocrine · 2025Article
- Advanced Magnetic Resonance Imaging Techniques for Localization of a Small Thyrotropin-Secreting Pituitary Tumor.JCEM case reports · 2025Article
- Diagnostic Challenges of Thyrotropin-Secreting Hypophyseal Macroadenoma Associated with Papillary Thyroid Carcinoma: Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Headache in pituitary adenomas: frequency, characteristics and outcome after treatment.Pituitary · 2025Article
- Thyroid-Stimulating Hormone-Secreting Pituitary Adenoma: Two Cases With Challenging Diagnosis and Management.Case reports in endocrinology · 2025Article
- Resistance to Thyroid Hormone Beta Due toJCEM case reports · 2024Article
- [Clinically active pituitary tumors].Innere Medizin (Heidelberg, Germany) · 2024Review
- A challenging case of a pituitary macroadenoma and toxic thyroid adenoma with inappropriate TSH secretion.Endocrinology, diabetes & metabolism case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyrotropin-secreting pituitary adenomas (TSH-omas) present with signs and symptoms of hyperthyroidism and they are characterized by elevated serum levels of free thyroid hormones with measurable TSH levels. TSH-omas are very infrequent, accounting for less than 1% of all pituitary adenomas, thus representing a very rare cause of hyperthyroidism. For this reason, data collected on these rare disorders are relatively few, but some new researches shed new light on the etiopathogenesis, the diagnosis and the treatment of such a remarkable disease. Since the same biochemical picture is present in the syndromes of thyroid hormone resistance (RTH), in particular in the form of pituitary RTH, failure in distinguishing these clinical entities may lead to improper patient management. Conversely, early diagnosis and correct treatment of TSH-omas may prevent the occurrence of neurological and endocrinological complications, thus leading to a better rate of cure. In the present short review article, the most relevant recent advances in the pathophysiology of TSH-omas are described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.